Skip to Main content Skip to Navigation
Journal articles

Urocontrin, a novel UT receptor ligand with a unique pharmacological profile.

Abstract : In recent years, several studies have demonstrated that urotensin II (UII) and urotensin II-related peptide (URP) can exhibit differential biological activity. So far, known antagonists of the urotensin II receptor (UT) are of limited usefulness for investigating the specific pathophysiological role of UII or URP. Therefore, identification of new compounds able to discriminate UII- and URP-associated biological activities is crucially needed. In the present study, we report preliminary data regarding the pharmacological properties of a novel UT ligand termed urocontrin, i.e. [Bip(4)]URP, that is able to reduce the ex vivo efficacy of hUII- but not URP-induced vasoconstriction in rat aortic rings. In vivo studies support the pharmacological profile described above. Although urocontrin exert some residual agonist activity, this compound should be useful for the rational design of potent molecules that would allow discriminating specific biological action mediated by UII or URP.
Document type :
Journal articles
Complete list of metadatas

Cited literature [38 references]  Display  Hide  Download

https://hal-riip.archives-ouvertes.fr/pasteur-01001676
Contributor : Nancy Laflamme <>
Submitted on : Wednesday, June 4, 2014 - 4:32:35 PM
Last modification on : Wednesday, April 17, 2019 - 12:21:21 PM
Long-term archiving on: : Tuesday, April 11, 2017 - 3:44:28 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Citation

David Chatenet, Quang-Trinh Nguyen, Myriam Létourneau, Jocelyn Dupuis, Alain Fournier. Urocontrin, a novel UT receptor ligand with a unique pharmacological profile.. Advances in Experimental Medicine and Biology, Kluwer, 2012, 83 (5), pp.608-15. ⟨10.1016/j.bcp.2011.12.009⟩. ⟨pasteur-01001676⟩

Share

Metrics

Record views

122